Debbie-Ann T. Shirley

1 month ago | onlinelibrary.wiley.com | John-Anthony Coppola |Debbie-Ann T. Shirley |Debbie-ann Shirley |Emily Martin |Emily and Sophie Martin |Varvara Probst

Cytomegalovirus (CMV) is a prevalent DNA virus that is a well-recognized cause of significant complications in post-transplant recipients. Emergence of CMV resistance to standard antiviral agents poses a substantial challenge for appropriate management post-transplantation. Currently, there are no pediatric heart transplant data on the use of novel agents such as letermovir for the management of resistant CMV infection.